Comparative Pharmacology
Head-to-head clinical analysis: FASENRA versus RAXIBACUMAB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FASENRA versus RAXIBACUMAB.
FASENRA vs RAXIBACUMAB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benralizumab is a humanized afucosylated monoclonal antibody that binds to the alpha subunit of the interleukin-5 receptor (IL-5Rα) expressed on eosinophils and basophils. This binding inhibits IL-5-mediated signaling and induces antibody-dependent cell-mediated cytotoxicity (ADCC), resulting in rapid and near-complete depletion of eosinophils from blood and tissues.
Raxibacumab is a monoclonal antibody that binds to the protective antigen (PA) component of Bacillus anthracis toxins, preventing PA from binding to host cell receptors and thereby inhibiting the intracellular entry of lethal factor and edema factor. This neutralizes the lethal and edema toxins, reducing pathogenicity.
30 mg subcutaneously every 4 weeks for the first 3 doses, then every 8 weeks thereafter.
Single intravenous dose of 40 mg/kg administered over 30 minutes.
None Documented
None Documented
Terminal half-life approximately 25 days (range 24–27 days), supporting every-4-week subcutaneous dosing.
Terminal elimination half-life approximately 12-24 hours (mean ~18 hours) in patients with normal renal function; half-life extends in renal impairment.
Degraded into small peptides and amino acids via general protein catabolism; no significant renal or biliary/fecal excretion of intact drug.
Primarily renal excretion as intact protein; >90% of administered dose recovered in urine over 48 hours.
Category C
Category C
Monoclonal Antibody, Anti-Interleukin-5 Receptor
Monoclonal Antibody